Trials / Terminated
TerminatedNCT04974359
A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia
Interventional, Randomized, Double-Blind, Crossover, Placebo-Controlled, Multiple-Dose Lu AG06466 Phase IB Study in Patients With Fibromyalgia Using Neuroimaging to Investigate Its Pharmacodynamic Effects on Central Pain Processing and Neuroinflammation
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out the effect of Lu AG06466 on the body in participants with fibromyalgia by assessing pain levels, brain signal changes, and psychiatric (mental) assessments.
Detailed description
This study will include 2 treatment periods and will utilize a crossover study design with a 7- to 14-day washout period between each 22-day treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AG06466 | Lu AG06466 - capsules |
| DRUG | Placebo | Placebo - capsules |
Timeline
- Start date
- 2021-06-24
- Primary completion
- 2022-01-26
- Completion
- 2022-01-26
- First posted
- 2021-07-23
- Last updated
- 2022-02-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04974359. Inclusion in this directory is not an endorsement.